Stock comparison
Haemonetics
Integra LifeSciences
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
IART
Integra LifeSciences
Market cap
$1.17B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | IART | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 26F | HAE |
| Benjamin Graham | 85A | 40D | HAE |
| Philip Fisher | 60C | 23F | HAE |
| Peter Lynch | 54C | 21F | HAE |
| Joel Greenblatt | 31F | 40D | IART |
| Charlie Munger | 54D | 22F | HAE |
| Terry Smith | 55D | 15F | HAE |
Side-by-side metrics
| Metric | HAE | IART |
|---|---|---|
| Market cap | $2.98B | $1.17B |
| P/E (TTM) | 24.8x | - |
| EV/EBIT | 14.1x | 42.6x |
| ROIC (TTM) | 8.37% | 3.49% |
| Gross margin | 55.74% | 53.21% |
| Net margin | 7.29% | -30.15% |
| Revenue CAGR 5y | 7.65% | 1.47% |
| EPS CAGR 5y | 24.62% | - |
| Debt / Equity | 1.5x | 2.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- Net margin7.29%vs -30.15%+124%
- Revenue CAGR 5y7.65%vs 1.47%+81%
- EV/EBIT14.1xvs 42.6x+67%
- Market cap$2.98Bvs $1.17B+61%
IART leads on
- P/E (TTM)-vs 24.8x+109%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.